A recent review in the International Journal of Biological Macromolecules provides a novel overview of 'virosome'-based nanovaccine production, its properties, and its application in viral ...

This research shows that an insect cells-baculovirus expression vector system can be used to create high-quality SARS-CoV-2 S protein for the implementation in a virosome-based COVID-19 vaccine ...

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe ...

Pevion Biotech’s existing investors have put another CHF10 million (about $9.7 million) into the firm to help fund continued progression of its pipeline of virosome-based vaccine candidates.

Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an ...

With its HIV-1 (human immunodeficiency virus type 1) vaccine candidate, produced through its proprietary virosome technology, Mymetics aims to provide both a first line of defense through mucosal ...

Pevion Biotech SA was the exclusive manufacturer for Mymetics' clinical stage HIV and malaria virosome vaccine candidates until they stopped operations. Consequently Mymetics has further secured ...

MYMETICS Corporation Acquires Virosome Biologicals B.V. Mymetics Corporation (http://www.mymetics.com) (OTC BB:MYMX.OB - News) announced today that it has signed a ...

Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its ...

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe ...